Acrobiosystems Co.,Ltd.

301080

CNE100004S13

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
39.44 ^CNY	-2.38%		-3.14%	-33.08%

Apr. 18	Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research	CI

Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.

January 18, 2024 at 03:44 am EST

From January 1, 2024 to January 17, 2024, the company has repurchased 112,200 shares, representing 0.09% for CNY 6 million. With this, the company has completed the repurchase of 273,800 shares, representing 0.23% for CNY 16 million under the buyback announced on July 18, 2023.

Latest news about Acrobiosystems Co.,Ltd.

Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18	CI
ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research	Apr. 10	CI
Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.	Jan. 18	CI
Acrobiosystems Co.,Ltd.'s Equity Buyback announced on July 18, 2023, has closed with 273,800 shares, representing 0.23% for CNY 16 million.	Jan. 16	CI
Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.	Jan. 03	CI
Acrobiosystems Launches Gmp Grade Dll4 Protein to Accelerate Stem Cell Manufacturing	Nov. 16	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.	23-10-10	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Acrobiosystems Co.,Ltd. Approves Board Elections	23-08-03	CI
Acrobiosystems Co.,Ltd. announces an Equity Buyback for CNY 30 million worth of its shares.	23-07-17	CI
Acrobiosystems Co.,Ltd. authorizes a Buyback Plan.	23-07-16	CI
ACROBiosystems, Through ACRO Certify and Under its Aneuro Brand, Announces Launch of in Vivo Electrophysiology Solutions for Neuroscience Research with Diagnostic Biochips	23-06-09	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
ACROBiosystems Launches New Logistics Center in Switzerland to Help Accelerate Drug Development Throughout Europe	22-11-18	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Certain A Shares of Acrobiosystems Co.,Ltd. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	22-10-18	CI
Shanghai Biaodu Biotech Co., Ltd. announced that it has received $3 million in funding from Baotou Hongyuan Investment Management Consultation Co., Ltd., Huaige Capital, Acrobiosystems Co.,Ltd.	22-09-22	CI
Acrobiosystems Co.,Ltd.(XSEC:301080) added to S&P Global BMI Index	22-09-19	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-21	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-13	CI
Baisi Medical Diagnostic Technology Co., Ltd. announced that it has received CNY 20 million in funding from Acrobiosystems Co.,Ltd., Beijing Juli Changxin Enterprise Management Consulting Partnership (Limited Partnership)	22-03-23	CI
Baisi Medical Diagnostic Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Acrobiosystems Co.,Ltd., Beijing Juli Changxin Enterprise Management Consulting Partnership (Limited Partnership), and another investor	22-03-17	CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI

Chart Acrobiosystems Co.,Ltd.

Duration

Period

More charts

Company Profile

Acrobiosystems Co Ltd is a China-based company specializing in providing recombinant protein and other key biological reagent products and technical services. The Company's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The Company's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Acrobiosystems Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.44 CNY

Average target price

56.78 CNY

Spread / Average Target

+43.95%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ACROBIOSYSTEMS CO.,LTD.	-33.08%	668M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals

Acrobiosystems Co.,Ltd.

Equities

301080

CNE100004S13

Pharmaceuticals

Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.

Latest news about Acrobiosystems Co.,Ltd.

Chart Acrobiosystems Co.,Ltd.

Company Profile

Income Statement Evolution

Ratings for Acrobiosystems Co.,Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals